RT Journal Article
T1 Neoadjuvant Biologic Therapy in the Surgical Management of Patients with Hidradenitis Suppurativa: A Cohort Study
A1 Salvador-Rodriguez, Luis
A1 Cuenca-Barrales, Carlos
A1 Arias-Santiago, Salvador
A1 Molina-Leyva, Alejandro
K1 Neoadjuvant therapy
K1 Hidradenitis suppurativa
K1 Patient care
K1 Patient care management
K1 Cohort studies
K1 Biological therapy
K1 Atención al paciente
K1 Terapia neoadyuvante
K1 Hidradenitis supurativa
K1 Manejo de atención al paciente
K1 Estudios de cohortes
K1 Terapia biológica
AB Hidradenitis suppurativa (HS) is a chronic skin disease characterized by recurrent flares of nodules, abscesses and fistulae, predominantly in the apocrine gland-bearing areas. These symptoms progress to scarring if not adequately treated, leading to functional limitations (1). Disease management is challenging, the 2 mainstays of treatment being biologic drugs and surgery. However, scientific evidence regarding the combined use of both therapies is scarce and is limited to a few studies (2–4). A clinical trial (SHARPS Study) is in progress on the safety and efficacy of peri-surgically administered adalimumab, but the results are not yet available (5).The objectives of this study were: to assess the clinical features of patients with HS undergoing surgery with neoadjuvant biologic treatment; to explore the complications of this combined approach; and to compare recurrence rates at 24 weeks after surgery between patients on concomitant biologic treatment and those who are not on biologic treatment.
PB Society for Publication of Acta Dermato-Venereologica
SN 0001-5555
YR 2020
FD 2020-08-19
LK http://hdl.handle.net/10668/3448
UL http://hdl.handle.net/10668/3448
LA en
NO Salvador-Rodriguez L, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Neoadjuvant Biologic Therapy in the Surgical Management of Patients with Hidradenitis Suppurativa: A Cohort Study. Acta Derm Venereol. 2020 Sep 8;100(16):adv00257.
DS RISalud
RD Mar 14, 2025